Valeant's (VRX) Amended Facility Expected, But Shares Remain Uninvestible - Piper
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/22/2026
Go back to Valeant's (VRX) Amended Facility Expected, But Shares Remain Uninvestible - Piper
August 18, 2016 3:40 PM EDT
(Updated - August 18, 2016 3:41 PM EDT)
Valeant Pharma (NYSE: VRX) announced the following on Thursday:
We are aware of the filing and have not been served yet. This T. Rowe Price complaint repeats allegations and claims as in the pending securities putative... More
August 18, 2016 1:55 PM EDT
Morgan Stanley maintained an Overweight rating on Valeant Pharmaceuticals (NYSE: VRX) with a price target of $42. Earlier the company announced that it has obtained the requisite lender approval for an amendment to its credit facility. Analyst David Risinger sees the news as a positive.
"In-line with our expectations, VRX amended its credit... More
August 18, 2016 8:37 AM EDT
(Reuters) - Valeant Pharmaceuticals International Inc (NYSE: VRX) (NYSE: VRX) said its lenders had approved an amendment to its credit facility, giving the drugmaker more flexibility to sell assets and repay loans by taking on other debt.
The embattled... More
August 18, 2016 8:01 AM EDT
Valeant Pharmaceuticals International, Inc. (NYSE: VRX) announced that it has obtained the requisite lender approval for an amendment to its credit facility. The Company expects to close the amendment next week, subject to customary closing conditions. The amendment will:
reduce the interest...
More
August 17, 2016 12:00 PM EDT
Valeant Pharma (NYSE: VRX) shares are reaching new session highs midday Wednesday. The stock is up well over 13 percent with high volume.
Notably, Morgan Stanley upgraded the stock earlier. For more color on the call, click here.
...
More
